Treatment-resistant depression (TRD) is, by definition, depression that hasn't responded adequately to standard interventions. If you've tried multiple antidepressants, therapy modalities, and lifestyle changes without finding lasting relief, you already know how exhausting that search can be. Ketamine therapy has offered genuine hope for many people with TRD—but not all ketamine programs are built to serve this population well.
The problem isn't ketamine itself. The problem is that many providers treat it like any other prescription: standardized doses, rigid protocols, and hard caps that don't account for the very nature of treatment resistance. If your depression hasn't responded to conventional approaches, why would a one-size-fits-all ketamine protocol be any different?
Understanding Treatment-Resistant Depression
Clinically, treatment-resistant depression is typically defined as major depressive disorder that has not responded to at least two adequate trials of antidepressant medications. But the lived experience goes far beyond that clinical definition. Many patients with TRD have tried far more than two medications. They've explored therapy, ECT, TMS, lifestyle interventions, and supplements. By the time they consider ketamine, they've often been struggling for years or decades.
This matters for dosing because TRD is not a mild condition. The neurobiological patterns underlying treatment resistance—including altered glutamate signaling, neuroinflammation, and impaired neuroplasticity—may require more robust intervention to disrupt. Research continues to explore optimal dosing for this population, but one thing is increasingly clear: the dose that helps someone with moderate, treatment-responsive depression may not be sufficient for someone whose brain has been resistant to multiple interventions.
Why Dose Flexibility Matters for TRD Patients
Ketamine works differently from traditional antidepressants. Rather than modulating serotonin or norepinephrine, it acts primarily on the NMDA glutamate receptor, triggering a cascade of neuroplastic changes that can rapidly alleviate depressive symptoms. The therapeutic response is dose-dependent, and the optimal dose varies significantly from person to person based on factors including:
-
Body weight and composition: A 120-pound patient and a 250-pound patient will metabolize ketamine differently.
-
Liver metabolism: Genetic variations in liver enzymes affect how quickly ketamine is broken down, influencing both duration and intensity of effect.
-
Severity and chronicity of depression: Longer-standing, more severe depression may require higher doses to achieve the neuroplastic shifts associated with therapeutic response.
-
Prior ketamine exposure: Patients who have been on ketamine therapy for an extended period may develop some degree of tolerance, requiring gradual dose adjustments to maintain efficacy.
-
Concurrent medications: Certain medications can interact with ketamine metabolism, effectively raising or lowering the functional dose.
Given this variability, it makes little clinical sense to impose a universal maximum dose. A cap that's appropriate for one patient may leave another well below their therapeutic threshold.
The Dose Cap Problem
Many at-home ketamine providers set maximum dose limits—commonly around 300mg per session or 1200mg per month. These caps are typically driven by operational and regulatory caution rather than by evidence suggesting that higher supervised doses are unsafe.
For patients with TRD, hitting a dose cap can be particularly devastating. Consider this scenario: after years of failed medications, you finally find something that works. You start ketamine therapy, respond well at a moderate dose, but over time your relief plateaus. Your provider increases your dose incrementally—until they can't anymore. You're told you've reached the maximum. Your options are to stay at a dose that no longer fully works or to stop treatment.
This is not a hypothetical. It's a situation we hear about regularly from patients who come to Kalm Health after being capped elsewhere.
Kalm Health's Approach: Dosing Guided by Response
At Kalm Health, we do not impose a hard maximum dose cap. This doesn't mean we prescribe recklessly—it means we prescribe individually. Every dose adjustment is based on a clinical evaluation of your response, side effects, and overall trajectory. Our clinicians are experienced with patients across the full dosing spectrum, including those who require above-standard doses for treatment-resistant conditions.
Our pricing reflects this commitment to flexibility:
-
Standard Plan: $124/month for patients within typical dose ranges
-
High-Dose Plan: $175/month (billed $349 every two months) for patients requiring above 1200mg/month
Both plans include ongoing clinical oversight, dose adjustments as needed, and direct communication with your prescribing clinician.
What the Research Suggests
While much of the ketamine research has focused on IV infusion protocols in clinical settings, the emerging body of evidence on sublingual (at-home) ketamine supports the principle that individualized dosing leads to better outcomes. Studies have consistently shown that treatment response varies widely among patients, and that dose optimization—rather than dose standardization—is associated with more durable symptom relief.
For TRD specifically, higher doses have shown promise in patients who did not respond to lower doses. This aligns with what clinicians who work with this population observe in practice: some patients simply need more to achieve the same neurobiological effect that others get at a standard dose.
Taking the Next Step
If you're living with treatment-resistant depression and your current ketamine provider has limited your options, you deserve to know that alternatives exist. Finding the right dose is not about chasing a number—it's about finding the point where your symptoms meaningfully improve and you can engage with your life again.
Kalm Health's free assessment is a simple starting point. It takes just a few minutes and helps our clinical team understand your history so we can determine whether our program is right for you. No pressure, no commitment—just a conversation about what's possible.
Frequently Asked Questions
What qualifies as treatment-resistant depression?
Treatment-resistant depression is generally defined as major depressive disorder that has not responded adequately to at least two different antidepressant medications taken at proper doses for sufficient duration. Many patients with TRD have tried significantly more interventions before exploring ketamine.
How does ketamine help treatment-resistant depression?
Ketamine acts on the NMDA glutamate receptor system, which is different from the serotonin and norepinephrine pathways targeted by traditional antidepressants. This mechanism can promote rapid neuroplastic changes, often providing relief within hours to days rather than weeks. For TRD patients, this alternative pathway can succeed where conventional medications have failed.
Is it safe to take ketamine above 1200mg per month?
When prescribed and monitored by an experienced clinician, doses above 1200mg/month can be appropriate for certain patients. Ketamine has been used safely in medical settings at much higher doses for decades. The key factors are proper clinical oversight, gradual titration, and ongoing monitoring of your response and any side effects.
How do I know if I need a higher ketamine dose?
Signs that your current dose may be insufficient include diminishing relief between sessions, a plateau in improvement despite consistent use, or incomplete symptom resolution. These observations should always be discussed with your prescribing clinician, who can evaluate whether a dose adjustment is appropriate based on your full clinical picture.
